Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 3Phase 1 3

Status

Unknown 11Completed 6Terminated 3Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Solid Tumor 1Advanced Tumors 1Advanced Solid Tumor 1

Interventions

Cyclophosphamide 98pembrolizumab 85Gemcitabine 81Carboplatin 62fludarabine 61Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 49Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 33Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26Pemetrexed 25atezolizumab 24Oxaliplatin 24Capecitabine 24fludarabine phosphate 22Filgrastim 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Terminated × camrelizumab × Clear all
NCT05799183 2024-12-31

A SHR-1210 BE Study on Healthy Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Terminated
12 enrolled

Advanced Tumors

NCT03871855 2023-06-05

A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Terminated
8 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT03182673 2022-09-01

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Terminated
31 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡